# Tucows Inc: financial statements, quarterly

TCX · Nasdaq · CIK 909494 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tcx.md) · [Financials](/companies/tcx/financials.md) · [Filings](/companies/tcx/filings.md) · [Insiders](/companies/tcx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tcx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [87.0](/filings/0001437749-24-033982.md) | [87.0 d](/filings/0001437749-25-007558.md) | [87.5](/filings/0001437749-24-015733.md) | [89.4](/filings/0001437749-24-025602.md) | [92.3](/filings/0001437749-24-033982.md) | [93.1 d](/filings/0001437749-25-007558.md) | [94.6](/filings/0001437749-26-015656.md) | [98.5](/filings/0000909494-26-000003.md) | [98.6](/filings/0001437749-25-033639.md) | [98.7 d](/filings/0001437749-26-008009.md) | [96.7](/filings/0001437749-26-015656.md) | [101](/filings/0000909494-26-000003.md) |
| Cost of revenue | $m | [70.2](/filings/0001437749-24-033982.md) | [69.1 d](/filings/0001437749-26-008009.md) | [69.1](/filings/0001437749-25-015557.md) | [68.6](/filings/0001437749-25-025490.md) | [70.1](/filings/0001437749-25-033639.md) | [71.4 d](/filings/0001437749-26-008009.md) | [71.1](/filings/0001437749-26-015656.md) | [76.4](/filings/0000909494-26-000003.md) | [74.4](/filings/0001437749-25-033639.md) | [74.5 d](/filings/0001437749-26-008009.md) | [72.5](/filings/0001437749-26-015656.md) | [74.8](/filings/0000909494-26-000003.md) |
| Gross profit | $m | [16.8](/filings/0001437749-24-033982.md) | [17.8 d](/filings/0001437749-26-008009.md) | [18.3](/filings/0001437749-25-015557.md) | [20.8](/filings/0001437749-25-025490.md) | [22.2](/filings/0001437749-25-033639.md) | [21.7 d](/filings/0001437749-26-008009.md) | [23.5](/filings/0001437749-26-015656.md) | [22.1](/filings/0000909494-26-000003.md) | [24.2](/filings/0001437749-25-033639.md) | [24.1 d](/filings/0001437749-26-008009.md) | [24.1](/filings/0001437749-26-015656.md) | [25.8](/filings/0000909494-26-000003.md) |
| Research and development | $m | [4.8](/filings/0001437749-24-033982.md) | [5.0 d](/filings/0001437749-26-008009.md) | [5.0](/filings/0001437749-25-015557.md) | [4.5](/filings/0001437749-25-025490.md) | [4.6](/filings/0001437749-25-033639.md) | [4.5 d](/filings/0001437749-26-008009.md) | [4.4](/filings/0001437749-26-015656.md) | [4.3](/filings/0000909494-26-000003.md) | [4.7](/filings/0001437749-25-033639.md) | [4.4 d](/filings/0001437749-26-008009.md) | [4.4](/filings/0001437749-26-015656.md) | [4.9](/filings/0000909494-26-000003.md) |
| Operating income | $m | [(17.2)](/filings/0001437749-24-033982.md) | [(16.1) d](/filings/0001437749-26-008009.md) | [(16.5)](/filings/0001437749-25-015557.md) | [(8.6)](/filings/0001437749-25-025490.md) | [(10.0)](/filings/0001437749-25-033639.md) | [(29.9) d](/filings/0001437749-26-008009.md) | [(2.0)](/filings/0001437749-26-015656.md) | [(2.9)](/filings/0000909494-26-000003.md) | [(9.6)](/filings/0001437749-25-033639.md) | [(9.0) d](/filings/0001437749-26-008009.md) | [(4.3)](/filings/0001437749-26-015656.md) | [(5.5)](/filings/0000909494-26-000003.md) |
| Interest expense | $m | [13.7](/filings/0001437749-24-033982.md) | [14.0 d](/filings/0001437749-24-010358.md) | [12.9](/filings/0001437749-24-015733.md) | [13.2](/filings/0001437749-25-025490.md) | [13.8](/filings/0001437749-25-033639.md) | [14.5 d](/filings/0001437749-26-008009.md) | [14.1](/filings/0001437749-26-015656.md) | [14.1](/filings/0000909494-26-000003.md) | [14.4](/filings/0001437749-25-033639.md) | [14.5 d](/filings/0001437749-26-008009.md) | [14.2](/filings/0001437749-26-015656.md) | [14.7](/filings/0000909494-26-000003.md) |
| Income tax | $m | [(0.8)](/filings/0001437749-24-033982.md) | [(1.3) d](/filings/0001437749-26-008009.md) | [1.8](/filings/0001437749-25-015557.md) | [1.2](/filings/0001437749-25-025490.md) | [3.1](/filings/0001437749-25-033639.md) | [1.9 d](/filings/0001437749-26-008009.md) | [2.2](/filings/0001437749-26-015656.md) | [2.3](/filings/0000909494-26-000003.md) | [2.5](/filings/0001437749-25-033639.md) | [1.6 d](/filings/0001437749-26-008009.md) | [2.4](/filings/0001437749-26-015656.md) | [3.1](/filings/0000909494-26-000003.md) |
| Net income | $m | [(22.8)](/filings/0001437749-24-033982.md) | [(23.4) d](/filings/0001437749-26-008009.md) | [(26.5)](/filings/0001437749-25-015557.md) | [(18.6)](/filings/0001437749-25-025490.md) | [(22.3)](/filings/0001437749-25-033639.md) | [(42.5) d](/filings/0001437749-26-008009.md) | [(15.1)](/filings/0001437749-26-015656.md) | [(15.6)](/filings/0000909494-26-000003.md) | [(23.0)](/filings/0001437749-25-033639.md) | [(22.0) d](/filings/0001437749-26-008009.md) | [(18.1)](/filings/0001437749-26-015656.md) | [(20.5)](/filings/0000909494-26-000003.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [(1.41)](/filings/0000909494-26-000003.md) | not reported | not reported | not reported | [(1.84)](/filings/0000909494-26-000003.md) |
| Basic EPS | $ per share | [(2.09)](/filings/0001437749-24-033982.md) | not reported | [(2.42)](/filings/0001437749-25-015557.md) | [(1.70)](/filings/0001437749-25-025490.md) | [(2.03)](/filings/0001437749-25-033639.md) | not reported | [(1.37)](/filings/0001437749-26-015656.md) | [(1.41)](/filings/0000909494-26-000003.md) | [(2.08)](/filings/0001437749-25-033639.md) | not reported | [(1.63)](/filings/0001437749-26-015656.md) | [(1.84)](/filings/0000909494-26-000003.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating, us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [111](/filings/0001437749-24-033982.md) | [92.7](/filings/0001437749-26-008009.md) | [66.6](/filings/0001437749-25-015557.md) | [39.3](/filings/0001437749-25-025490.md) | [75.2](/filings/0001437749-25-033639.md) | [56.9](/filings/0001437749-26-008009.md) | [38.1](/filings/0001437749-26-015656.md) | [52.0](/filings/0000909494-26-000003.md) | [54.1](/filings/0001437749-25-033639.md) | [46.8](/filings/0000909494-26-000003.md) | [44.3](/filings/0001437749-26-015656.md) | [44.2](/filings/0000909494-26-000003.md) |
| Current assets | $m | [266](/filings/0001437749-23-030034.md) | [243](/filings/0001437749-25-007558.md) | [214](/filings/0001437749-24-015733.md) | [189](/filings/0001437749-24-025602.md) | [222](/filings/0001437749-24-033982.md) | [205](/filings/0001437749-26-008009.md) | [194](/filings/0001437749-25-015557.md) | [212](/filings/0001437749-25-025490.md) | [209](/filings/0001437749-25-033639.md) | [203](/filings/0000909494-26-000003.md) | [200](/filings/0001437749-26-015656.md) | [198](/filings/0000909494-26-000003.md) |
| Total assets | $m | [814](/filings/0001437749-23-030034.md) | [798](/filings/0001437749-25-007558.md) | [780](/filings/0001437749-24-015733.md) | [758](/filings/0001437749-24-025602.md) | [799](/filings/0001437749-24-033982.md) | [759](/filings/0001437749-26-008009.md) | [742](/filings/0001437749-25-015557.md) | [742](/filings/0001437749-25-025490.md) | [735](/filings/0001437749-25-033639.md) | [731](/filings/0000909494-26-000003.md) | [729](/filings/0001437749-26-015656.md) | [728](/filings/0000909494-26-000003.md) |
| Current liabilities | $m | [188](/filings/0001437749-23-030034.md) | [201](/filings/0001437749-25-007558.md) | [208](/filings/0001437749-24-015733.md) | [204](/filings/0001437749-24-025602.md) | [199](/filings/0001437749-24-033982.md) | [200](/filings/0001437749-26-008009.md) | [193](/filings/0001437749-25-015557.md) | [201](/filings/0001437749-25-025490.md) | [195](/filings/0001437749-25-033639.md) | [330](/filings/0000909494-26-000003.md) | [337](/filings/0001437749-26-015656.md) | [346](/filings/0000909494-26-000003.md) |
| Long-term debt | $m | not reported | [212](/filings/0001437749-24-010358.md) | not reported | not reported | not reported | [195](/filings/0001437749-25-007558.md) | not reported | not reported | not reported | [190](/filings/0001437749-26-008009.md) | not reported | not reported |
| Shareholders' equity | $m | [30.0](/filings/0001437749-23-030034.md) | [9.9](/filings/0001437749-26-008009.md) | [(15.9)](/filings/0001437749-24-025602.md) | [(33.1)](/filings/0001437749-24-033982.md) | [(53.1)](/filings/0001437749-24-033982.md) | [(95.3)](/filings/0001437749-26-008009.md) | [(108)](/filings/0001437749-25-025490.md) | [(122)](/filings/0001437749-25-033639.md) | [(144)](/filings/0001437749-25-033639.md) | [(164)](/filings/0000909494-26-000003.md) | [(181)](/filings/0000909494-26-000003.md) | [(201)](/filings/0000909494-26-000003.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(6.9)](/filings/0001437749-24-033982.md) | [9.0 d](/filings/0001437749-26-008009.md) | [(5.7)](/filings/0001437749-25-015557.md) | [(4.7)](/filings/0001437749-25-025490.md) | [(4.6)](/filings/0001437749-25-033639.md) | [(4.8) d](/filings/0001437749-26-008009.md) | [(11.3)](/filings/0001437749-26-015656.md) | [6.6](/filings/0000909494-26-000003.md) | [1.5](/filings/0001437749-25-033639.md) | [(2.6) d](/filings/0001437749-26-008009.md) | [3.5](/filings/0001437749-26-015656.md) | [1.9](/filings/0000909494-26-000003.md) |
| Capital expenditure | $m | [22.6](/filings/0001437749-24-033982.md) | [14.6 d](/filings/0001437749-26-008009.md) | [14.3](/filings/0001437749-25-015557.md) | [16.0](/filings/0001437749-25-025490.md) | [14.5](/filings/0001437749-25-033639.md) | [11.7 d](/filings/0001437749-26-008009.md) | [5.4](/filings/0001437749-26-015656.md) | [3.5](/filings/0000909494-26-000003.md) | [3.9](/filings/0001437749-25-033639.md) | [4.4 d](/filings/0001437749-26-008009.md) | [5.5](/filings/0001437749-26-015656.md) | [5.1](/filings/0000909494-26-000003.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [10.8](/filings/0001437749-23-030034.md) | [10.8](/filings/0001437749-24-015733.md) | [10.8](/filings/0001437749-24-025602.md) | [10.9](/filings/0001437749-24-033982.md) | [10.9](/filings/0001437749-25-015557.md) | [11.0](/filings/0001437749-25-025490.md) | [11.0](/filings/0001437749-25-033639.md) | [11.0](/filings/0001437749-26-015656.md) | [11.1](/filings/0000909494-26-000003.md) | [11.1](/filings/0001437749-25-033639.md) | [11.1](/filings/0001437749-26-015656.md) | [11.1](/filings/0000909494-26-000003.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 11,182,112 at 2026-08-05, from the cover of the [10-Q filed 2026-08-06](/filings/0000909494-26-000003.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:28 ET. No prices; not investment advice.